Monopost (Latanoprost)

Latanoprost, the active ingredient in Monopost, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is employed in the management of glaucoma and ocular hypertension in adult patients.

GNH USA supplies Monopost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets. The company leverages a robust distribution network to meet the demand of eye‑care professionals globally, and all shipments are accompanied by full documentation and temperature‑controlled packaging where required.

Latanoprost acts on the prostaglandin pathway to reduce intraocular pressure in glaucoma‑related conditions.

Open-angle glaucoma: lowers intraocular pressure to prevent optic nerve damage Ocular hypertension: reduces elevated eye pressure to lower risk of glaucoma development Elevated intraocular pressure: decreases pressure to protect visual function

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: transient hyperemia of the conjunctiva. - Eye irritation: burning or stinging sensation after instillation. - Increased iris pigmentation: gradual darkening of the eye colour. - Eyelash changes: lengthening and increased thickness of eyelashes.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract requiring medical attention. - Macular edema: swelling of the central retina that can impair vision.

Before initiating Latanoprost therapy, consider the following precautions to ensure safe and effective use.

- Monitor intraocular pressure: schedule regular IOP measurements to assess response. - Assess for ocular infections: avoid use in eyes with active bacterial or viral infection. - Discontinue contact lens wear: remove lenses before and for several hours after instillation. - Pregnancy and lactation: safety unknown; prescribe only if potential benefit outweighs risk. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Combined use with other prostaglandin analogues: may cause excessive IOP lowering and hypotony. - Concurrent topical NSAIDs: may diminish Latanoprost’s IOP‑lowering effect. - Systemic carbonic anhydrase inhibitors: increased risk of ocular side effects.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP reduction may require monitoring. - Alpha‑adrenergic agonist drops: potential alteration of pressure‑control dynamics.